Officials at Solvias, a CRO headquartered in Kaiseraugst, Switzerland, say the company is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, NC. It is the company’s latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development, according to Solvias.

The 50,000 ft2 facility, expected to be completed in 2025 and bring 170+ jobs to the Raleigh-Durham area, will serve as Solvias’ North American hub for large molecule analytical services and will offer cell-based potency assays, advanced NGS capabilities, and related testing services supporting multiple biologic modalities, noted Archie Cullen, CEO of the company.

From the outset, the new testing center will support characterization and release testing of CGTs and other advanced therapies, including adeno-associated virus (AAV) gene therapies, mRNA therapies, and antibody drug conjugates. [Solvias]
“Our new center strongly complements our biologics and CGT sites in Europe and expands our world-class testing capabilities in the U.S. Our team is thrilled to bring our newest center of excellence to Research Triangle Park, a leading research and development center and burgeoning hub for the life science industry,” said Cullen.

In addition to the new RTP lab and Solvias’ headquarters in Kaiseraugst, Switzerland, the four other centers of excellence are located in Basel, Switzerland; Hombourg, France; Utrecht, The Netherlands; and Canton, MA, in the United States.

Previous articleStrategies for Determining Critical Quality Attributes of Nucleic Acid Therapeutics and Their Carriers
Next articleUnveiling the Potential of Digital Intelligence to Empower Pharmaceutical Companies